Title : Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial.

Pub. Date : 2022 Feb

PMID : 34797531






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Doxorubicin DNA damage inducible transcript 3 Homo sapiens